U.S. Markets open in 44 mins

This tiny biotech spun a quick $2 billion from $12 million

Emma Court
This tiny biotech spun a quick $2 billion from $12 million

Endocyte licensed a prostate cancer drug a year ago for an upfront payment of $12 million. Now, it’s being bought by the Swiss pharma giant Novartis for more than $2 billion.